Danish Medicines Council could be a roadblock for sclerosis drug Kesimpta

Kesimpta has not blown the council away, a draft assessment of the Genmab-developed drug’s clinical value suggests.


Although sclerosis drug Kesimpta has been on somewhat of a worldwide victory tour, and generated sales of almost DKK 1.5bn (USD 230m) in the first three quarters of this year, the Danish Medicines Council is not convinced of its advantages.

Kesimpta, which was originally developed by Genmab and is now owned by Novartis, was assessed by the council, which has now sent its report on to a hearing process at Novartis.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs